Curated Wealth Partners LLC Purchases 1,865 Shares of Novo Nordisk A/S (NYSE:NVO)

Curated Wealth Partners LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 38.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,698 shares of the company’s stock after purchasing an additional 1,865 shares during the quarter. Curated Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $576,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL bought a new position in shares of Novo Nordisk A/S in the second quarter valued at $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the 3rd quarter valued at about $28,000. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S during the 3rd quarter valued at about $42,000. Carolina Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the third quarter worth approximately $48,000. Finally, M&R Capital Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 260.5% in the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after purchasing an additional 297 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $87.94 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a market cap of $394.65 billion, a price-to-earnings ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The firm’s 50-day simple moving average is $95.62 and its two-hundred day simple moving average is $115.55.

Analysts Set New Price Targets

NVO has been the subject of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.